Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 4liposomal doxorubicin 2Interleukin-12 Subunit p35 2Interleukin-12 2Early Intervention, Educational 2Docetaxel 2veliparib 1tipifarnib 1temsirolimus 1sargramostim 1ixabepilone 1entinostat 1cediranib 1Watchful Waiting 1Vorinostat 1Vinorelbine 1Therapeutics 1Taxes 1TIC10 compound 1Standard of Care 1Sirolimus 1Radiotherapy 1Pyridoxine 1Psychiatric Rehabilitation 1Propranolol 1Practice Guidelines as Topic 1Physical Therapy Modalities 1Pemetrexed 1Paclitaxel 1Mifepristone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms, Male × Pyridoxine × Gynecologic × Clear all
NCT00245050 2011-12-30

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

Case Comprehensive Cancer Center

Phase 3 Completed
34 enrolled 9 charts
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Male, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡